vs

Side-by-side financial comparison of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) and VerifyMe, Inc. (VRME). Click either name above to swap in a different company.

VerifyMe, Inc. is the larger business by last-quarter revenue ($5.0M vs $2.9M, roughly 1.7× NEUROONE MEDICAL TECHNOLOGIES Corp). NEUROONE MEDICAL TECHNOLOGIES Corp runs the higher net margin — -49.7% vs -66.7%, a 17.0% gap on every dollar of revenue. On growth, VerifyMe, Inc. posted the faster year-over-year revenue change (-7.4% vs -11.7%). Over the past eight quarters, NEUROONE MEDICAL TECHNOLOGIES Corp's revenue compounded faster (44.9% CAGR vs -5.2%).

NeuroOne Medical Technologies Corp is a medical technology company specializing in the development and commercialization of diagnostic and therapeutic neurological devices for conditions including epilepsy, movement disorders, and chronic pain. Its core products include minimally invasive cortical monitoring electrodes and neurostimulation systems, primarily serving neurology and neurosurgical care providers across North America.

VerifyMe, Inc. is a technology provider specializing in identity verification, anti-counterfeiting, and brand protection solutions. Its offerings include secure authentication tools, supply chain traceability systems, and customer engagement platforms, serving consumer goods, pharmaceutical, and retail sectors across North America and select global markets.

NMTC vs VRME — Head-to-Head

Bigger by revenue
VRME
VRME
1.7× larger
VRME
$5.0M
$2.9M
NMTC
Growing faster (revenue YoY)
VRME
VRME
+4.3% gap
VRME
-7.4%
-11.7%
NMTC
Higher net margin
NMTC
NMTC
17.0% more per $
NMTC
-49.7%
-66.7%
VRME
Faster 2-yr revenue CAGR
NMTC
NMTC
Annualised
NMTC
44.9%
-5.2%
VRME

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
NMTC
NMTC
VRME
VRME
Revenue
$2.9M
$5.0M
Net Profit
$-1.4M
$-3.4M
Gross Margin
54.2%
41.2%
Operating Margin
-59.0%
-68.2%
Net Margin
-49.7%
-66.7%
Revenue YoY
-11.7%
-7.4%
Net Profit YoY
-180.5%
-38.4%
EPS (diluted)
$-0.03
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NMTC
NMTC
VRME
VRME
Q4 25
$2.9M
Q3 25
$2.7M
$5.0M
Q2 25
$1.7M
$4.5M
Q1 25
$1.4M
$4.5M
Q4 24
$3.3M
Q3 24
$272.3K
$5.4M
Q2 24
$825.8K
$5.4M
Q1 24
$1.4M
$5.8M
Net Profit
NMTC
NMTC
VRME
VRME
Q4 25
$-1.4M
Q3 25
$-1.6M
$-3.4M
Q2 25
$-1.5M
$-291.0K
Q1 25
$-2.3M
$-571.0K
Q4 24
$1.8M
Q3 24
$-2.4M
Q2 24
$-2.8M
$-346.0K
Q1 24
$-2.9M
$-553.0K
Gross Margin
NMTC
NMTC
VRME
VRME
Q4 25
54.2%
Q3 25
55.8%
41.2%
Q2 25
53.9%
35.2%
Q1 25
55.6%
33.4%
Q4 24
58.9%
Q3 24
51.8%
34.9%
Q2 24
34.1%
39.1%
Q1 24
28.3%
39.2%
Operating Margin
NMTC
NMTC
VRME
VRME
Q4 25
-59.0%
Q3 25
-50.0%
-68.2%
Q2 25
-111.2%
-7.1%
Q1 25
-193.3%
-13.3%
Q4 24
52.3%
Q3 24
-52.8%
Q2 24
-338.3%
-10.0%
Q1 24
-209.5%
-11.2%
Net Margin
NMTC
NMTC
VRME
VRME
Q4 25
-49.7%
Q3 25
-59.1%
-66.7%
Q2 25
-88.5%
-6.4%
Q1 25
-163.8%
-12.8%
Q4 24
54.5%
Q3 24
-44.6%
Q2 24
-335.1%
-6.5%
Q1 24
-207.3%
-9.6%
EPS (diluted)
NMTC
NMTC
VRME
VRME
Q4 25
$-0.03
Q3 25
$-0.05
$-0.26
Q2 25
$-0.03
$-0.02
Q1 25
$-0.07
$-0.05
Q4 24
$0.06
Q3 24
$-0.23
Q2 24
$-0.10
$-0.03
Q1 24
$-0.11
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NMTC
NMTC
VRME
VRME
Cash + ST InvestmentsLiquidity on hand
$3.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.4M
$11.1M
Total Assets
$8.6M
$13.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NMTC
NMTC
VRME
VRME
Q4 25
$3.6M
Q3 25
$6.6M
Q2 25
$8.0M
Q1 25
$1.3M
Q4 24
$1.1M
Q3 24
$1.5M
$2.6M
Q2 24
$1.6M
$2.9M
Q1 24
$2.4M
$2.8M
Total Debt
NMTC
NMTC
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$500.0K
Q2 24
$600.0K
Q1 24
$800.0K
Stockholders' Equity
NMTC
NMTC
VRME
VRME
Q4 25
$6.4M
Q3 25
$7.1M
$11.1M
Q2 25
$8.2M
$14.4M
Q1 25
$1.1M
$14.6M
Q4 24
$2.9M
Q3 24
$822.0K
$10.3M
Q2 24
$3.0M
$12.3M
Q1 24
$3.9M
$12.4M
Total Assets
NMTC
NMTC
VRME
VRME
Q4 25
$8.6M
Q3 25
$10.8M
$13.3M
Q2 25
$10.8M
$17.2M
Q1 25
$4.5M
$17.1M
Q4 24
$6.5M
Q3 24
$5.4M
$14.8M
Q2 24
$4.9M
$17.5M
Q1 24
$5.4M
$17.9M
Debt / Equity
NMTC
NMTC
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.05×
Q2 24
0.05×
Q1 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NMTC
NMTC
VRME
VRME
Operating Cash FlowLast quarter
$-3.1M
$243.0K
Free Cash FlowOCF − Capex
$-3.2M
FCF MarginFCF / Revenue
-109.1%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NMTC
NMTC
VRME
VRME
Q4 25
$-3.1M
Q3 25
$-1.5M
$243.0K
Q2 25
$-1.5M
$710.0K
Q1 25
$-56.1K
$-404.0K
Q4 24
$208.0K
Q3 24
$-11.0M
$-10.0K
Q2 24
$-2.4M
$372.0K
Q1 24
$-2.2M
$-60.0K
Free Cash Flow
NMTC
NMTC
VRME
VRME
Q4 25
$-3.2M
Q3 25
Q2 25
$-1.5M
Q1 25
Q4 24
$183.6K
Q3 24
$-11.1M
$-12.0K
Q2 24
$-2.4M
$369.0K
Q1 24
$-2.2M
$-62.0K
FCF Margin
NMTC
NMTC
VRME
VRME
Q4 25
-109.1%
Q3 25
Q2 25
-89.0%
Q1 25
Q4 24
5.6%
Q3 24
-4088.4%
-0.2%
Q2 24
-287.6%
6.9%
Q1 24
-160.2%
-1.1%
Capex Intensity
NMTC
NMTC
VRME
VRME
Q4 25
1.4%
Q3 25
Q2 25
2.8%
Q1 25
Q4 24
0.7%
Q3 24
44.1%
0.0%
Q2 24
1.8%
0.1%
Q1 24
2.3%
0.0%
Cash Conversion
NMTC
NMTC
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.12×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NMTC
NMTC

Segment breakdown not available.

VRME
VRME

Proactive Services$4.2M83%
Other$869.0K17%

Related Comparisons